Tenofovir Disoproxil Fumarate

ARV U.S. Brand Name

Viread

ARV Abbreviation(s)

TDF

U.S. FDA Label

Tenofovir disoproxil fumarate (Viread) Labeling (Package Insert)

ARV Class

Nucleoside reverse transcriptase inhibitors

First U.S. Approval

October 26, 2001

U.S. Manufacturer

Gilead Sciences

Formulations

Strength	Formulation	Image	Description	Boosted
150 mg	Tablet	X	triangular white tablet with 150 imprint	No
200 mg	Tablet	X	round whit tablet with 200 imprint	No
250 mg	Tablet	X	oval white tablet with 250 imprint	No
300 mg	Tablet	X	light blue oval tablet with 300 imprint	No
40 mg of tenofovir DF per 1 g of powder		X	white bottle, vired, tenofovir disoproxil fumarate, oral powder 40 mg/scoop imprint	No

Generic Available?

FDCs

Doravirine / Lamivudine / Tenofovir DF

Efavirenz / Emtricitabine / Tenofovir DF

Elvitegravir / Cobicistat / Tenofovir DF / Emtricitabine

Emtricitabine / Rilpivirine / Tenofovir DF

Emtricitabine / Tenofovir DF

Lamivudine / Tenofovir DF

Efavirenz / Lamivudine / Tenofovir DF

Assistance Programs

Gilead Advancing Access

Displaying 1 - 44 of 44

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Rilpivirine (IM) Tenofovir disoproxil fumarate	Green: Administer standard doses	Administer standard doses
Darunavir TDF 911	Green: Administer standard doses	Administer standard doses		Cmax increase 16%, AUC increase 21%, Cmin increase 24%	300 mg once daily	Cmax increase 24%, AUC increase 22%, Cmin increase 37%
Atazanavir TDF 775	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy with lower atazanavir concentrationss. Potential for increased tenofovir adverse effects	Atazanavir Cmax decreased 28%, AUC decreased 25%, Cmin decreased 26%, Ritonavir Cmax decreased 28%, AUC decreased 25%, Cmin no significant change	300 mg daily on days 15-42	Not reported	Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. Do not coadminister TDF with unboosted atazanavir (400 mg).
Tenofovir disoproxil fumarate LDV/SOF 753	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of TDF adverse effects (e.g. renal function decline)	AUC increase 40%-98%, Cmin increase 55-80% when TDF coadministered with rilpivirine and efavirenz or various PIs, INSTIs, and NNRTIs	90 / 400 mg once daily	Not studied	If coadministering, monitor for TDF adverse effects. Avoid use if CrCl >60 ml / min.
Tenofovir disoproxil fumarate DRV 752	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of TDF and / or darunavir adverse effects	Cmax increase 24%, AUC increase 22%, Cmin increase 37%	300 mg BID with ritonavir 100 mg BID	Cmax increase 16%, AUC increase 21%, Cmin increase 24%	If coadministering, monitor for TDF adverse effects (e.g. renal function decline)
Tenofovir disoproxil fumarate SOF/VEL/VOX 751	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Increase AUC 30-80% when given with various ARV containing TDF		Not studied	If coadministering, monitor for TDF adverse effects
Tenofovir disoproxil fumarate SOF/VEL 750	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Cmax increased 36%; AUC increased 35%; Cmin increased 45%	400 / 100mg once daily	Not studied	If coadministering, monitor for TDF adverse effects
Tenofovir disoproxil fumarate Valganciclovir 749	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of TDF and / or ganciclovir adverse effects	Not studied (may increase TDF levels)		Not studied (may increase ganciclovir levels)	If coadministering, monitor for adverse effects
Tenofovir disoproxil fumarate Ganciclovir 748	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of TDF and / or ganciclovir adverse effects	Not studied (may increase TDF levels)		Not studied (may increase ganciclovir levels)	If coadministering, monitor for adverse effects
Tenofovir disoproxil fumarate Adefovir 747	Red: Avoid combination	Do not coadminister: Potential for increased levels of TDF	Potential for increased risk of TDF adverse effects and / or increased concentration of other renally eliminated drugs	No significant change	10 mg once daily	No significant change	Avoid combination and use alternative agents
Tenofovir disoproxil fumarate Ribavirin 746	Green: Administer standard doses	Administer standard doses		No significant change	800 mg x 1	No significant change
Tenofovir disoproxil fumarate RIF 745	Green: Administer standard doses	Administer standard doses		No significant change	600 mg once daily	No significant change
Tenofovir disoproxil fumarate EFV 744	Green: Administer standard doses	Administer standard doses		No significant change	600 mg once daily	No significant change
Tenofovir disoproxil fumarate Daclatasvir 743	Green: Administer standard doses	Administer standard doses		No significant change	60 mg once daily	No significant change
Tenofovir disoproxil fumarate DTG 742	Green: Administer standard doses	Administer standard doses		No significant change	50 mg once daily	No significant change
Tenofovir disoproxil fumarate Methadone 741	Green: Administer standard doses	Administer standard doses		Not studied	40-110 mg once daily (individual patients on stable dose)	No significant change
Tenofovir disoproxil fumarate ABC 740	Green: Administer standard doses	Administer standard doses		No significant change	300 mg x 1	No significant change
Tenofovir disoproxil fumarate FTC 739	Green: Administer standard doses	Administer standard doses		No significant change	200 mg once daily	No significant change
Tenofovir disoproxil fumarate Buprenorphine / naloxone 738	Green: Administer standard doses	Administer standard doses		No significant change	14-16 mg once daily	No significant change
Tenofovir disoproxil fumarate EE/NGM 737	Green: Administer standard doses	Administer standard doses		No significant change	1 tab daily	No significant change
Tenofovir disoproxil fumarate Entecavir 736	Green: Administer standard doses	Administer standard doses		No significant change	1 mg once daily	No significant change
Tenofovir disoproxil fumarate RAL 735	Green: Administer standard doses	Administer standard doses		Cmax decrease 23%, AUC decrease 10%, Cmin decrease 13%	400 mg BID	Cmax increase 64%, AUC increase 49%
Tenofovir disoproxil fumarate 3TC 734	Green: Administer standard doses	Administer standard doses		No significant change	150 mg BID	Cmax decrease 24%
Tenofovir disoproxil fumarate ETR 733	Green: Administer standard doses	Administer standard doses		Cmax increase 15%, AUC increase 15%, Cmin increase 19%	200 mg BID	Cmax decrease 19%, AUC decrease 19%, Cmin decrease 18%
Tenofovir disoproxil fumarate SOF 732	Green: Administer standard doses	Administer standard doses		Cmax increase 25%	400 mg x 1	Cmax decrease 19%
Tenofovir disoproxil fumarate G/P 731	Green: Administer standard doses	Administer standard doses	(when given with EFV / FTC)	Not studied (may increase TDF levels)		Not studied
Tenofovir disoproxil fumarate RPV 730	Green: Administer standard doses	Administer standard doses	Potentially increased risk of TDF adverse effects	Cmax increase 19%, AUC increase 23%, Cmin increase 24%	150 mg once daily	No significant change	Use recommended dose of rilpivirine 25 mg
Tenofovir disoproxil fumarate ATV/c 729	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Potentially increased risk of TDF adverse effects and decreased efficacy of atazanavir	Not studied (may increase TDF levels)		Not studied (may decrease atazanavir levels)	If coadministering atazanavir, cobicistat, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg
Tenofovir disoproxil fumarate ATV 728	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased tenofovir effects, decreased atazanavir effects	Cmax increase 34%, AUC increase 37%, Cmin increase 29%	300 mg once daily with 100 mg ritonavir daily	Cmax decrease 28%, AUC decrease 25%, Cmin decrease 23%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Tenofovir disoproxil fumarate ATV 727	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased tenofovir effects, decreased atazanavir effects	Cmax increase 14%, AUC increase 24%, Cmin increase 22%	400 mg once daily with a light meal	Cmax decrease 21%, AUC decrease 25%, Cmin decrease 40%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Tenofovir disoproxil fumarate ATV 726	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased atazanavir and tenofovir effects	Cmax increase 39%, AUC increase 55%, Cmin increase 70%	400 mg once daily with 100 mg ritonavir daily	Cmax increase 31%, AUC increase 38%, Cmin increase 33%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Emtricitabine TDF 689	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	No significant change
Emtricitabine TDF 688	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	No significant change
Emtricitabine TDF 687	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	No significant change
Emtricitabine TDF 686	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	No significant change
Emtricitabine TDF 685	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	No significant change
Emtricitabine TDF 684	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	no significant
Emtricitabine TDF 672	Green: Administer standard doses	Administer standard doses		Cmin increase 20%	300 mg once daily x 7 days	AUC increased 13%, Cmax increased 17%
Nevirapine TDF 643			Potential early virologic failure	Not studied			Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients
Raltegravir TDF 290	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 49%; Cmax increased 64%	300 mg daily	Not reported
Dolutegravir TDF 99	Green: Administer standard doses	Administer standard doses		Cmax decreased 3%, AUC increased 1%, Cmin decreased 8%	300 mg once daily	Cmax increased 9%, AUC increased 12%, Cmin increased 19%
Fostemsavir RAL + TDF 16	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 23%, AUC increased 7%, Cmin increased 17%	RAL 400 mg BID, TDF 300 mg once daily	Not reported
Fostemsavir TDF 4	Green: Administer standard doses	Administer standard doses		Temsavir Cmax decreased 1%, Cmin increased 13%	300 mg once daily	Cmax increased 18%, AUC increased 19%, Cmin increased 28%
Tenofovir Disoproxil Fumarate

Subscribe to Tenofovir Disoproxil Fumarate